Abstracts tagged "Hydroxychloroquine"

Abstract Number: 8L • 2017 ACR/ARHP Annual Meeting
Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
Dilpreet Singh¹, Leila Muhieddine², Douglas Einstadter³ and Stanley Ballou⁴, ¹Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ²Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ³Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ⁴Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of chronic rheumatic diseases. Its long-standing use has been associated with retinopathy in a daily and…
Abstract Number: 1651 • 2017 ACR/ARHP Annual Meeting
Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity
Anna Viola Taulaigo¹, Maria Francisca Moraes-Fontes¹, Eunice Patarata², Sara Guerreiro Castro² and Arnaldo Dias-Santos³, ¹Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, ²Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (CHLC), Lisbon, Portugal, Lisbon, Portugal, ³Serviço de Oftalmologia, Hospital de Santo António dos Capuchos, CHLC, Lisbon, Portugal, Lisbon, Portugal
Background/Purpose: Despite effectiveness and favourable safety profile, antimalarials have the potential to cause irreversible macular retinopathy and vision loss. Screening methods still vary among clinicians…
Abstract Number: 1964 • 2017 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review
April Jorge¹, Sharan K. Rai² and Hyon K. Choi², ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. While generally well-tolerated and…
Abstract Number: 2035 • 2017 ACR/ARHP Annual Meeting
Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
Sahil Koppikar¹ and Henry Averns², ¹Department of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Private Practice, Kingston, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is used widely for the treatment of inflammatory arthritides and systemic lupus erythematosus. Recent publications have shown that HCQ toxicity is not…
Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Hua Chen¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…
Abstract Number: 2614 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴, Lucy H. Young⁵, Ronald B. Melles⁶, Michael F. Marmor⁷, Karen H. Costenbader⁸, Rosalind Ramsey-Goldman⁹, S. Sam Lim¹⁰, John M. Esdaile¹¹, Ann E. Clarke¹², Murray Urowitz¹³, Anca Askanase¹⁴, Cynthia Aranow¹⁵, Michelle Petri¹⁶ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Ophthalmology,, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ⁶Department of Ophthalmology, Kaiser Permanente, Redwood City, CA, ⁷Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹FSM, Northwestern University, Chicago, IL, ¹⁰Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹¹Arthritis Research Canada, Richmond, BC, Canada, ¹²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁴Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ¹⁵Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) care. The major long-term adverse event risk is vision-threatening toxic retinopathy. The 2012 EULAR,…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…
Abstract Number: 2635 • 2017 ACR/ARHP Annual Meeting
Dosechecker: Solving the Hydroxychloroquine Dosing Dilemma with a Smart Phone App
Elliot Perlman¹, Robert Friday², Paul Greenberg³, David Browning⁴ and Joan Miller⁵, ¹Rhode Island Eye Institute, Providence, RI, ²Division of Rheumatology, Department of Medicine, Newton-Wellesley Hospital, Newton, MA, ³Division of Ophthalmology, Alpert Medical School, Brown University, Providence, RI, ⁴Charlotte Eye Ear, Nose, and Throat Associates, Charlotte, NC, ⁵Department of Ophthalmology, Harvard Medical School and Massachusetts Eye and Ear Institute, Boston, MA
Background/Purpose: Hydroxychloroquine retinopathy (HCR) is a potentially blinding but largely preventable disease. The true prevalence of HCR is unknown among the 350,000 Americans who take…
Abstract Number: 442 • 2017 ACR/ARHP Annual Meeting
Early Treatment with Hydroxychloroquine Is Associated with Better Long-Term Outcomes in a Group of Hispanic Patients with Rheumatoid Arthritis
Franchesca Cruz-Pérez¹, Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez², Naydi Pérez-Ríos³, Noelia Rodríguez-Pérez¹, Grissel Ríos⁴ and Luis M. Vilá⁵, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ³Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁴Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁵Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) has a disease-modifying effect in rheumatoid arthritis (RA) patients but also it is associated with improved lipid profile, and decreased risk for…
Abstract Number: 1296 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Level Decreases throughout Pregnancy: Implications for Maternal and Neonatal Outcomes
Stephen Balevic¹, Michael Cohen-Wolkowiez², Amanda M. Eudy³, Laura E. Schanberg⁴ and Megan E. B. Clowse⁵, ¹Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC, ²Pharmacometrics Center, Duke Clinical Research Institute, Durham, NC, ³Duke University Medical Center, Chapel Hill, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Duke University Medical Center, Durham, NC
Background/Purpose: Pregnancies in women with active rheumatic disease often result in poor neonatal outcomes. Prior data suggests that hydroxychloroquine (HCQ) can reduce disease activity and…
Abstract Number: 1297 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data
Amanda M. Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Mokbel⁴, Cecilia Nalli⁵, Laura Andreoli⁵, Angela Tincani⁶, Yair Molad⁷, Stephen Balevic⁸ and Megan E. B. Clowse¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany, ⁴Department of Rheumatology and Rehabilitation, Cairo University Hospital, Cairo, Egypt, ⁵Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁸Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Our current knowledge about how to treat lupus in pregnancy derives from small prospective or retrospective cohorts, and how best to manage lupus nephritis…
Abstract Number: 737 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Whole Blood Levels Do Not Associate with Hydroxychloroquine Retinopathy
Michelle Petri¹, Wei Fu² and Syed Mahmood Shah³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The American Academy of Ophthalmology guidelines on hydroxychloroquine retinopathy were recently revised (Ophthalmology 2016;1-9). These guidelines recommend optical coherence tomography (OCT) with multifocal electroretinogram…
Abstract Number: 741 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Is Not Associated with Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients
Samya Mohammad, Megan E. B. Clowse, Amanda Eudy and Lisa Criscione-Schreiber, Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: Hydroxychloroquine (HCQ) is frequently used to treat autoimmune diseases. The HCQ package insert and online drug information resources report an increased risk of hemolytic…
Abstract Number: 751 • 2016 ACR/ARHP Annual Meeting
Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
Michelle Petri¹, Ying Qu², John Conklin³, Kelley Brady⁴, Robert Apilado⁵ and Thierry Dervieux⁶, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴R&D, Exagen Diagnostics, Vista, CA, United Kingdom, ⁵Exagen Diagnostics, vista, CA, United Kingdom, ⁶Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: We evaluated the relationships between disease activity measures and C4d split products on erythrocytes (EC4d) in SLE subjects from a subset of the Hopkins…
Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Rajaie Namas¹, Corey Powell² and J. Michelle Kahlenberg³, ¹Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ²Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…